| Assay ID | Title | Year | Journal | Article |
|---|
| AID1254839 | Antiproliferative activity against human GBM2 cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by WST-1 method | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID1703248 | Antitumor activity against NPG mouse xenografted with human Raji cell assessed as decrease in tumor volume at 5 mg/kg, ip measured on the 1 day | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | F10, a new camptothecin derivative, was identified as a new orally-bioavailable, potent antitumor agent. |
| AID1667195 | Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay | 2020 | Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
| Enhanced cellular uptake efficiency of DCM probes or SN38 conjugating with phenylboronic acids. |
| AID1254842 | Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID621765 | Toxicity in mouse Meth-A cells xenografted BALB/c mouse assessed as mortality at 100 mg/kg, iv | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
| Synthesis of phenanthroindolizidine alkaloids and evaluation of their antitumor activities and toxicities. |
| AID1254844 | Selectivity index, ratio of IC50 for normal human astrocytes to IC50 for human GBM2 cells | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID1703244 | Toxicity in NPG mouse xenografted with human Raji cells assessed as body weight loss at 5 mg/kg, ip measured after 5 day | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | F10, a new camptothecin derivative, was identified as a new orally-bioavailable, potent antitumor agent. |
| AID1703233 | Toxicity in nude BALB/c mouse xenografted with human HCT-116 cells assessed as reduction in body weight at 20 mg/kg, po dosed once the every 2 day for upto 24 days | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | F10, a new camptothecin derivative, was identified as a new orally-bioavailable, potent antitumor agent. |
| AID1254845 | Antiproliferative activity against human GBM3 cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by WST-1 method | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID1703253 | Antitumor activity against NPG mouse xenografted with human Raji cell assessed as decrease in tumor volume at 5 mg/kg, ip measured after 5 day | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | F10, a new camptothecin derivative, was identified as a new orally-bioavailable, potent antitumor agent. |
| AID621764 | Toxicity in mouse Meth-A cells xenografted BALB/c mouse assessed as mortality at 50 mg/kg, iv | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
| Synthesis of phenanthroindolizidine alkaloids and evaluation of their antitumor activities and toxicities. |
| AID1703258 | Antitumor activity against NPG mouse xenografted with human Raji cell assessed as tumor growth inhibition at 5 mg/kg, ip measured after 5 day | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | F10, a new camptothecin derivative, was identified as a new orally-bioavailable, potent antitumor agent. |
| AID252303 | Tumor growth delay of human HCT116 colorectal carcinoma in mice after intravenous administration at dose of 100 mg/kg | 2004 | Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
| Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. |
| AID1254846 | Antiproliferative activity against human GBM3 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID1703239 | Toxicity in NPG mouse xenografted with human Raji cells assessed as body weight loss at 5 mg/kg, ip measured on the 1 day | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | F10, a new camptothecin derivative, was identified as a new orally-bioavailable, potent antitumor agent. |
| AID612142 | Cytotoxicity against human U373MG cells expressing human intestinal carboxylesterase after 4 days in drug free medium by coulter counter | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
| Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones. |
| AID1254843 | Selectivity index, ratio of IC50 for normal human astrocytes to IC50 for human GBM1 cells | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID1254838 | Antiproliferative activity against human GBM1 cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by WST-1 method | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID621771 | Toxicity in human HCT116 cells xenografted nude mouse assessed as mortality at 135 mg/kg, ip | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
| Synthesis of phenanthroindolizidine alkaloids and evaluation of their antitumor activities and toxicities. |
| AID1254840 | Antiproliferative activity against human GBM1 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID1254847 | Selectivity index, ratio of IC50 for normal human astrocytes to IC50 for human GBM3 cells | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID1254841 | Antiproliferative activity against human GBM2 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). |
| AID621762 | Antitumor activity against mouse Meth-A cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 100 mg/kg, iv administered on day 1, 5, 9 and measured on day 21 post-implantation relative to control | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
| Synthesis of phenanthroindolizidine alkaloids and evaluation of their antitumor activities and toxicities. |
| AID621761 | Antitumor activity against mouse Meth-A cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 50 mg/kg, iv administered on day 1, 5, 9 and measured on day 21 post-implantation relative to control | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
| Synthesis of phenanthroindolizidine alkaloids and evaluation of their antitumor activities and toxicities. |
| AID621768 | Antitumor activity against human HCT116 cells xenografted in nude mouse assessed as tumor growth inhibition at 135 mg/kg, ip administered 10 times on days 1 to 5 and 8 to 12 measured on day 21 post-implantation relative to control | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
| Synthesis of phenanthroindolizidine alkaloids and evaluation of their antitumor activities and toxicities. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
| Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |